Arrigo F G Cicero1, Matteo Pirro2, Gerald F Watts3, Dimitri P Mikhailidis4, Maciej Banach5,6, Amirhossein Sahebkar7,8. 1. Department of Medical and Surgical Sciences, University of Bologna, Via Albertoni 15, Bologna, Italy. 2. Unit of Internal Medicine, Angiology and Arteriosclerosis Diseases, Department of Medicine, University of Perugia, Perugia, Italy. 3. Department of Cardiology, Lipid Disorders Clinic, Royal Perth Hospital, Perth, WA, Australia. 4. Department of Clinical Biochemistry, Royal Free Hospital Campus, University College London Medical School, University College London, London, United Kingdom. 5. Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113, Lodz, Poland. 6. Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland. 7. Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, 9177948564, Iran. sahebkara@mums.ac.ir. 8. School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. sahebkara@mums.ac.ir.
Abstract
INTRODUCTION: Uric acid (UA), the final product of purine catabolism, may be associated with an increased risk of cardiovascular disease. AIM: The aim of this meta-analysis of randomized placebo-controlled trials was to evaluate whether lowering serum UA (SUA) levels with allopurinol is associated with improved flow-mediated dilation (FMD), a validated marker of early vascular damage. METHODS: A literature search was carried out from inception until 20 June 2017. Meta-analysis was performed using an inverse variance-weighted, random-effects model with standardized mean difference (SMD) as the effect size estimate. RESULTS: Meta-analysis of data from the ten eligible randomized controlled trials (RCTs), with 670 subjects, suggested a significant increase in FMD following allopurinol treatment (weighted mean difference [WMD] 1.79%, 95% confidence interval [CI] 1.01-2.56, p < 0.001; I 2: 86.77%). The effect size was robust and remained significant after omission of each single study. Subgroup analyses of RCTs based on the administered dose or duration of treatment did not reveal any significant impact of these variables on FMD change. Nor was a significant association found between allopurinol-induced changes in SUA levels and FMD (slope 0.46, p = 0.253), whereas baseline FMD significantly influenced the degree of FMD improvement following allopurinol treatment (slope 0.52, p = 0.022). Nitroglycerin-mediated dilation was not altered by allopurinol treatment (WMD 0.88%, 95% CI - 1.15-2.91, p = 0.395; I 2: 80.88%). CONCLUSION: This meta-analysis of available RCTs suggests a significant benefit from allopurinol intake in increasing FMD in humans, independent of its effect on SUA levels.
INTRODUCTION:Uric acid (UA), the final product of purine catabolism, may be associated with an increased risk of cardiovascular disease. AIM: The aim of this meta-analysis of randomized placebo-controlled trials was to evaluate whether lowering serum UA (SUA) levels with allopurinol is associated with improved flow-mediated dilation (FMD), a validated marker of early vascular damage. METHODS: A literature search was carried out from inception until 20 June 2017. Meta-analysis was performed using an inverse variance-weighted, random-effects model with standardized mean difference (SMD) as the effect size estimate. RESULTS: Meta-analysis of data from the ten eligible randomized controlled trials (RCTs), with 670 subjects, suggested a significant increase in FMD following allopurinol treatment (weighted mean difference [WMD] 1.79%, 95% confidence interval [CI] 1.01-2.56, p < 0.001; I 2: 86.77%). The effect size was robust and remained significant after omission of each single study. Subgroup analyses of RCTs based on the administered dose or duration of treatment did not reveal any significant impact of these variables on FMD change. Nor was a significant association found between allopurinol-induced changes in SUA levels and FMD (slope 0.46, p = 0.253), whereas baseline FMD significantly influenced the degree of FMD improvement following allopurinol treatment (slope 0.52, p = 0.022). Nitroglycerin-mediated dilation was not altered by allopurinol treatment (WMD 0.88%, 95% CI - 1.15-2.91, p = 0.395; I 2: 80.88%). CONCLUSION: This meta-analysis of available RCTs suggests a significant benefit from allopurinol intake in increasing FMD in humans, independent of its effect on SUA levels.
Authors: Benjamin R Szwejkowski; Stephen J Gandy; Sushma Rekhraj; John G Houston; Chim C Lang; Andrew D Morris; Jacob George; Allan D Struthers Journal: J Am Coll Cardiol Date: 2013-08-28 Impact factor: 24.094
Authors: Michelle P Kao; Donald S Ang; Stephen J Gandy; M Adnan Nadir; J Graeme Houston; Chim C Lang; Allan D Struthers Journal: J Am Soc Nephrol Date: 2011-06-30 Impact factor: 10.121
Authors: Sushma Rekhraj; Stephen J Gandy; Benjamin R Szwejkowski; M Adnan Nadir; Awsan Noman; J Graeme Houston; Chim C Lang; Jacob George; Allan D Struthers Journal: J Am Coll Cardiol Date: 2013-03-05 Impact factor: 24.094
Authors: Arrigo F G Cicero; Federica Fogacci; Raffaele Ivan Cincione; Giuliano Tocci; Claudio Borghi Journal: Med Princ Pract Date: 2020-10-09 Impact factor: 1.927
Authors: Gerwyn Morris; Basant K Puri; Lisa Olive; Andre Carvalho; Michael Berk; Ken Walder; Lise Tuset Gustad; Michael Maes Journal: BMC Med Date: 2020-10-19 Impact factor: 8.775
Authors: Massimo Nardone; Mary McCarthy; Chris I Ardern; Heather Edgell; Olga Toleva; Lynne E Nield; Steven E S Miner Journal: CJC Open Date: 2020-09-25